Atara Biotherapeutics
Supports Pierre Fabre’s global EBV-targeted tab-cel program through a lean partner-led operating model.
$9.20
After-hours close+0.07 (+0.77%)
At close$9.13(−1.30%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.14 | — | — |
| Aug 2026 | −$0.32 | −$0.32 | −1.6% |
| Aug 2026 | −$0.32 | −$0.32 | −1.6% |
| May 2026 | −$0.33 | −$0.29 | +12.0% |
| Mar 2026 | −$0.09 | −$0.25 | −177.8% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | −$0.14 | — | — | $1.0M | — | — |
| Aug 12, 2026 | −$0.32 | −$0.32 | −1.6% | $550.0K | $630.0K | +14.5% |
| Aug 11, 2026 | −$0.32 | −$0.32 | −1.6% | $550.0K | $630.0K | +14.5% |
| May 12, 2026 | −$0.33 | −$0.29 | +12.0% | $2.9M | $516.0K | −82.2% |
| Mar 16, 2026 | −$0.09 | −$0.25 | −177.8% | $3.4M | $1.6M | −51.2% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Nov 12, 2025 | ||||||
| Aug 11, 2025 | ||||||
| May 15, 2025 | ||||||
| Mar 7, 2025 | ||||||
| Nov 12, 2024 | ||||||
| Aug 12, 2024 | ||||||
| May 9, 2024 | ||||||
| Mar 28, 2024 | ||||||
| Nov 1, 2023 | ||||||
| Aug 8, 2023 | ||||||
| May 8, 2023 | ||||||
| Feb 8, 2023 | ||||||
| Nov 8, 2022 | ||||||
| Aug 8, 2022 | ||||||
| May 5, 2022 | ||||||
| Feb 28, 2022 | ||||||
| Nov 4, 2021 | ||||||
| Aug 9, 2021 | ||||||
| May 4, 2021 | ||||||
| Mar 1, 2021 | ||||||
| Nov 9, 2020 | ||||||
| Aug 5, 2020 | ||||||
| May 6, 2020 | ||||||
| Feb 27, 2020 | ||||||
| Nov 7, 2019 | ||||||
| Aug 8, 2019 | ||||||
| May 9, 2019 | ||||||
| Feb 26, 2019 | ||||||
| Nov 6, 2018 | ||||||
| Aug 1, 2018 | ||||||
| May 8, 2018 | ||||||
| Feb 27, 2018 | ||||||
| Nov 9, 2017 | ||||||
| Aug 7, 2017 | ||||||
| May 4, 2017 | ||||||
| Mar 9, 2017 | ||||||
| Nov 4, 2016 | ||||||
| Aug 8, 2016 | ||||||
| May 5, 2016 | ||||||
| Mar 3, 2016 | ||||||
| Nov 5, 2015 | ||||||